<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591600</url>
  </required_header>
  <id_info>
    <org_study_id>IVM-DOX</org_study_id>
    <nct_id>NCT04591600</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients</brief_title>
  <official_title>Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkarkh Health Directorate-Baghdad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkarkh Health Directorate-Baghdad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate&#xD;
      outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with&#xD;
      standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus&#xD;
      standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an&#xD;
      urgent need to try old re-purposed drugs on COVID-19. Methods: Randomized controlled study on&#xD;
      70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with&#xD;
      200ug/kg PO of Ivermectin per day for 2 days along with 100mg PO doxycycline twice per day&#xD;
      for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate&#xD;
      and 22 severe and zero critical patients) on standard therapy. The time to recovery, the&#xD;
      progression of the disease, and the mortality rate were the outcome-assessing parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">October 14, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The effect of the experimental drugs to reduce the mortality rate (death rate) of treated patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of progression disease</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>rate of patients under treatment who undergo progression of disease to a more advanced stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>time needed by treated patients to recover (become symptoms free and polymerase chain reaction, or PCR, negative)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ivermectin-Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin and Doxycyline</intervention_name>
    <description>Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.</description>
    <arm_group_label>Ivermectin-Doxycycline</arm_group_label>
    <other_name>Stromectol and Doxycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard care&#xD;
Acetaminophen 500mg on need&#xD;
Vitamin C 1000mg twice/ day&#xD;
Zinc 75-125 mg/day&#xD;
Vitamin D3 5000IU/day&#xD;
Azithromycin 250mg/day for 5 days&#xD;
Oxygen therapy/ C-Pap if needed&#xD;
dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed&#xD;
Mechanical ventilation, if needed</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ivermectin-Doxycycline</arm_group_label>
    <other_name>Control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 patients at any stage of this disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients of allergic history to Ivermectin or to doxycyline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Akarkh Healt hdirectorate</name>
      <address>
        <city>Baghdad</city>
        <zip>14222</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alkarkh Health Directorate-Baghdad</investigator_affiliation>
    <investigator_full_name>Ahmed Sahib Abdulamir</investigator_full_name>
    <investigator_title>M.B.Ch.,B., Phd Virology, Professor</investigator_title>
  </responsible_party>
  <keyword>Ivermectin</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

